These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 27100305

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [Danaparoid sodium for dialysis in heparin-associated thrombocytopenia].
    Ben Ami R, Rachmimov R, Berliner S.
    Harefuah; 1999 Mar 01; 136(5):361-4, 419. PubMed ID: 10914239
    [Abstract] [Full Text] [Related]

  • 23. Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia.
    Olin DA, Urdaneta F, Lobato EB.
    J Cardiothorac Vasc Anesth; 2000 Dec 01; 14(6):707-9. PubMed ID: 11139115
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery.
    Koster A, Meyer O, Hausmann H, Kuppe H, Hetzer R, Mertzlufft F.
    J Clin Anesth; 2000 Jun 01; 12(4):324-7. PubMed ID: 10960207
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Treatment of heparin-induced thrombocytopenia in cardiovascular patients.
    Matthai WH.
    Expert Opin Pharmacother; 2006 Feb 01; 7(3):267-76. PubMed ID: 16448321
    [Abstract] [Full Text] [Related]

  • 28. Anticoagulative management of patients requiring left ventricular assist device implantation and suffering from heparin-induced thrombocytopenia type II.
    Christiansen S, Jahn UR, Meyer J, Scheld HH, Van Aken H, Kehrel BE, Hammel D.
    Ann Thorac Surg; 2000 Mar 01; 69(3):774-7. PubMed ID: 10750760
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Clinical experience with Danaparoid-sodium: measures to be taken in heparin-induced thrombocytopenia].
    Chirurg; 1998 Nov 01; 69(11 Suppl Massnahme):1-4. PubMed ID: 9853175
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases.
    Fernandes P, Mayer R, MacDonald JL, Cleland AG, Hay-McKay C.
    Perfusion; 2000 Nov 01; 15(6):531-9. PubMed ID: 11131218
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Danaparoid in pregnancy in cases of heparin intolerance - use in 59 cases].
    Schindewolf M, Magnani HN, Lindhoff-Last E.
    Hamostaseologie; 2007 May 01; 27(2):89-97. PubMed ID: 17479171
    [Abstract] [Full Text] [Related]

  • 37. Heparin-induced thrombocytopenia type II on hemodialysis: switch to danaparoid.
    Neuhaus TJ, Goetschel P, Schmugge M, Leumann E.
    Pediatr Nephrol; 2000 Aug 01; 14(8-9):713-6. PubMed ID: 10955913
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Current agents for the treatment of patients with heparin-induced thrombocytopenia.
    Warkentin TE.
    Curr Opin Pulm Med; 2002 Sep 01; 8(5):405-12. PubMed ID: 12172444
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.